Le rôle d’Akt dans la réponse cellulaire aux dommages à l’ADN induits par les ultraviolets dans les cellules de mélanomes humains

Le mélanome malin est l’un des cancers les plus mortels dont l’incidence continue à augmenter chaque année avec peu de traitement efficace à long terme. Il est causé et initié principalement par l’exposition excessive aux rayons ultraviolets engendrant des photoproduits hautement génotoxiques. Il est bien connu que la cascade de signalisation PI3K/Akt joue un rôle crucial dans la régulation des processus qui sont généralement dérégulés durant le développement tumoral comme la prolifération, le contrôle du cycle cellulaire et l’apoptose. Néanmoins, l’implication de cette voie moléculaire dans la réponse aux dommages à l’ADN est peu caractérisée. Chez les mammifères, trois isoformes de la protéine kinase Akt ont été identifiées: Akt1, Akt2 et Akt3. Bien qu’elles soient très homologues en termes de séquence, plusieurs études ont montré que ces isoformes ont des fonctions biologiques distinctes, et nous suggérons qu’elles puissent contribuer différemment à la régulation de la réponse génotoxique. Les objectifs de ce projet étaient de: (i) évaluer l’activation d’Akt dans les cellules de mélanomes (ii) déterminer l’impact de l’inhibition de cette activité sur la régulation de la réponse cellulaire aux UV (iii) vérifier si la perte d’expression de l’un ou de l’autre des isoformes d’Akt peut réguler la réponse aux UV. Nous avons démontré qu’Akt est transitoirement hyperactivée par phosphorylation suite aux irradiations UV dans les lignées cellulaires de mélanomes. Afin de déterminer l'importance de cette activation dans la réponse cellulaire aux UV, notre approche était de diminuer (i) la phosphorylation d’Akt par l’usage d’inhibiteurs pharmacologiques ou (ii) l’expression de chaque isoforme d’Akt par l’approche des ARN interférents. Nous avons montré que l’inhibition de la phosphorylation d’Akt amène à l’augmentation du taux de l’apoptose induit par les UV d’une manière isoforme spécifique, alors qu’elle n’a aucun effet sur la régulation de la voie de réparation par excision de nucléotides (NER), qui est la seule voie humaine pour éliminer les dommages à l’ADN induits par les UV. En somme, notre étude constitue un nouvel aspect qui permet de mieux comprendre les mécanismes moléculaires du développement de mélanomes malins suites aux irradiations ultraviolettes.

Activation de la voie oncogénique mTOR par les formes mutées de l'isocitrate déshydrogénase 1/2 retrouvées chez les gliomes

Une des caractéristiques principales des cellules cancéreuses est la reprogrammation de leur métabolisme énergétique. Des mutations d’enzymes impliquées dans différentes voies métaboliques sont récurrentes chez plusieurs tumeurs, contribuant ainsi à la dérégulation de ces cellules et à l’oncogénèse. C’est le cas de l’isocitrate déshydrogénase 1 (IDH1) et 2 (IDH2), responsables de la conversion de l’isocitrate en α-kétoglutarate dans le cycle de l’acide citrique. Ces enzymes sont fréquemment mutées chez les gliomes, acquérant ainsi la capacité de convertir l’α-kétoglutarate en 2-hydroxyglutarate (2HG), un oncométabolite inhibant les oxygénases α-kétoglutarate dépendantes parmi lesquelles figure notamment KDM4A, une déméthylase de lysines. À la recherche de nouvelles voies oncogéniques potentiellement régulées par les formes mutées de IDH1/2, nous avons initialement observé que les mutations de ces deux enzymes et de PTEN, un régulateur négatif de la voie mTOR, étaient mutuellement exclusives chez les gliomes. Ceci suggère que les mutations de IDH1/2 reproduiraient certains effets engendrés par les mutations de PTEN, créant ainsi un environnement oncogénique similaire. Nous avons observé que les formes mutées de IDH1/2 stimulent l’activation de mTOR grâce à la production et l’accumulation de 2HG. Cette activation repose en partie sur l’inhibition de KDM4A par cet oncométabolite. KDM4A est impliqué dans la stabilisation de DEPTOR, un inhibiteur de mTOR. Ainsi, l’inhibition de KDM4A par le 2HG entraîne la déstabilisation de DEPTOR et, par conséquent, l’activation de mTOR. Nos travaux ont donc permis l’identification d’un nouveau mécanisme oncogénique régulé par les formes mutées de IDH1/2 retrouvées chez les gliomes, soit l’activation de mTOR.

Toxicidade induzida pelos peptídeos AB42 e AB25-35 em modelo de cultura organotípica de hipocampo de ratos

O crescimento da expectativa de vida média da população mundial tem sido acompanhado do aumento na prevalência de doenças neurodegenerativas, como a doença de Parkinson, isquemia cerebral e, especialmente, a doença de Alzheimer. A doença de Alzheimer (DA) caracteriza-se por um crescente declínio na função mental e memória do paciente. Estes sintomas são explicados por uma profunda perda neuronal e pela presença de alterações estruturais no tecido cerebral: as placas senis, extracelulares e os emaranhados neurofibrilares, intracelulares. O passo que desencadeia a neurodegeneração na DA é ainda objeto de estudo, mas a hipótese mais aceita atualmente é a de que a secreção anormal do peptídeo β amilóide (Aβ), principal componente das placas senis, dê início ao processo. O presente trabalho teve como objetivos investigar a toxicidade induzida pelo peptídeo Aβ1-42 e seu fragmento, o peptídeo Aβ25-35 em culturas organotípicas de hipocampo de ratos. Na primeira parte do trabalho, investigamos a toxicidade induzida pela exposição de culturas organotípicas de hipocampo de ratos a 10 ou 20 μM do peptídeo Aβ1-42, por 24 ou 72 h. Além disso, investigamos o envolvimento das proteínas iNOS e GSK-3β no mecanismo de morte celular induzida pelo peptídeo Aβ1-42. Na segunda parte do trabalho, investigamos a toxicidade induzida pelo fragmento Aβ25-35 na concentração de 25 μM, nos tempos de 1, 3, 6, 12, 24 ou 48 h de exposição às culturas organotípicas, e seu efeito sobre as proteínas Akt, GSK-3β e PTEN. A morte celular foi quantificada pela incorporação do iodeto de propídeo, corante marcador excluído de células sadias, e as proteínas foram quantificadas por imunodetecção com o uso de anticorpos específicos. Nossos resultados mostraram que o peptídeo Aβ1-42 apresentou toxicidade nas concentrações de 10 e 20 μM, induzindo a uma considerável morte celular após 72 h de exposição. A análise do imunoconteúdo da proteína iNOS mostrou um aumento significativo em relação ao controle, após 72 h de exposição ao peptídeo e na concentração de 20 μM. Os resultados obtidos na segunda parte do trabalho mostraram uma morte celular significativa apenas após 48 h de exposição ao peptídeo Aβ25- 35 na concentração de 25 μM. O tratamento com peptídeo Aβ25-35 levou ao aumento no estado de fosforilação da proteína Akt após 6 h de exposição e também da proteína GSK-3β, um potencial substrato da Akt. Após 12 h de exposição ao peptídeo, observamos uma diminuição de ambas as proteínas (Akt e GSK-3β). Porém, após 24 h de exposição ao peptídeo, a proteína Akt continua menos fosforilada enquanto que a proteína GSK-3β apresenta um novo pico de fosforilação. O imunoconteúdo da proteína fosfatase PTEN apresentou um aumento significativo em 24 h e 48 h. Os resultados do presente estudo mostraram que o tratamento das culturas organotípicas de hipocampo de ratos com o peptídeo Aβ1-42 como com o fragmento Aβ25-35 apresentou toxicidade após um período de aproximadamente 48 h de tratamento, e mostrou ser um bom modelo para o estudo de sua toxicidade. Com relação ao mecanismo investigado, os dados sugerem que a proteína iNOS pode estar envolvida na toxicidade induzida pelo peptídeo Aβ1-42. Além disso, sugerem que o fragmento Aβ25-35 possa exercer sua toxicidade através da inibição da via de sobrevivência celular PI3-K, por diminuir a fosforilação/ativação da proteína Akt, parecendo envolver a proteína fosfatase PTEN, principal regulador negativo da via PI3-K/Akt.

Alterações genéticas e epigenéticas em meningiomas na população paraense

Os meningiomas são os tumores intracranianos mais frequentes, originando-se das meninges que revestem o cérebro e cordão espinhal. Apesar de terem sido um dos primeiros neoplasmas sólidos estudados citogeneticamente, ainda são escassos os estudos genéticos e epigenéticos nesses tumores. O presente trabalho teve como objetivo investigar alterações genéticas e epigenéticas que pudessem contribuir na iniciação e progressão tumoral em meningiomas na população paraense. Essa tese está subdivida em três capítulos. No Capítulo I foi investigada a associação entre o polimorfismo MTHFR C677T e meningioma em 23 pacientes da população paraense, utilizando 96 indivíduos sem histórico de lesões pré-neoplásicas como grupo controle. Essa associação não foi encontrada, apesar de sugerir um aumento não estatisticamente significante no risco de desenvolver meningioma em portadores do genótipo TT quando comparados ao genótipo CC. No Capítulo II foi avaliado o padrão de metilação em duas famílias do microRNA124 em meningiomas na população paraense. Hipermetilação na região promotora de miRN124a2 e miRNA124a3 parece ser um evento frequente, uma vez que foi encontrada em 73,9% e 69,56% das amostras analisadas, respectivamente. No Capítulo III, foi analisado o padrão de metilação dos genes APC, BRCA1, CDH1, CDH13, CDKN2A, DAPK1, ESR1, FHIT, GSTP1, MGMT, MLH1, NEUROG1, PDLIM4, PTEN, RARB, RASSF1, RUNX3, SOCS1, TIMP3, TP73, VHL e WIF1 em um meningioma de grau I e um de grau II através de uma placa comercial desenvolvida através da tecnologia MethylScreen. O padrão de metilação do gene CDKN2B também foi analisado na amostra coletada em 25 pacientes com meningioma através da conversão por bissulfito, PCR e sequenciamento direto. O gene RASSF1A apresentou-se metilado em 16,73% e 63,66% dos sítios CpGs analisados na amostra de meningioma de grau I e grau II, respectivamente. O gene RUNX3 se apresentou metilado apenas na amostra de grau II em 52,88% dos sítios CpG analisados. Nossos resultados apontam a importância das alterações epigenéticas na tumorigênese e progressão tumoral em meningiomas.

Análise de genes envolvidos na neurotransmissão, formação e manutenção sináptica em indivíduos com transtornos do espectro do Autismo

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Metformin and soybean-derived bioactive molecules attenuate the expansion of stem cell-like epithelial subpopulation and confer apoptotic sensitivity in human colon cancer cells

Colorectal cancer (CRC) is a disease whose genesis may include metabolic dysregulation. Cancer stem cells are attractive targets for therapeutic interventions since their aberrant expansion may underlie tumor initiation, progression, and recurrence. To investigate the actions of metabolic regulators on cancer stem cell-like cells (CSC) in CRC, we determined the effects of soybean-derived bioactive molecules and the anti-diabetes drug metformin (MET), alone and together, on the growth, survival, and frequency of CSC in human HCT116 cells. Effects of MET (60 μM) and soybean components genistein (Gen, 2 μM), lunasin (Lun, 2 μM), β-conglycinin (β-con, 3 μM), and glycinin (Gly, 3 μM) on HCT116 cell proliferation, apoptosis, and mRNA/protein expression and on the frequency of the CSC CD133(+)CD44(+) subpopulation by colonosphere assay and fluorescence-activated cell sorting/flow cytometry were evaluated. MET, Gen, and Lun, individually and together, inhibited HCT116 viability and colonosphere formation and, conversely, enhanced HCT116 apoptosis. Reductions in frequency of the CSC CD133(+)CD44(+) subpopulation with MET, Gen, and Lun were found to be associated with increased PTEN and reduced FASN expression. In cells under a hyperinsulinemic state mimicking metabolic dysregulation and without and with added PTEN-specific inhibitor SF1670, colonosphere formation and frequency of the CD133(+)CD44(+) subpopulation were decreased by MET, Lun and Gen, alone and when combined. Moreover, MET + Lun + Gen co-treatment increased the pro-apoptotic and CD133(+)CD44(+)-inhibitory efficacy of 5-fluorouracil under hyperinsulinemic conditions. Results identify molecular networks shared by MET and bioavailable soy food components, which potentially may be harnessed to increase drug efficacy in diabetic and non-diabetic patients with CRC.

Identificação de genes de predisposição à síndrome dos carcinomas de mama e tireoide por sequenciamento total do exoma

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Potenciais microRNAs circulantes como biomarcadores de Leucemia Mieloide Crônica - Fase Crônica: recém diagnosticada e tratada com mesilato de imatinibe

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients

OBJECTIVES: The phosphatidylinositol 3-kinase/AKT axis is an important cell-signaling pathway that mediates cell proliferation and survival, two biological processes that regulate malignant cell growth. The phosphatidylinositol 3-kinase CA gene encodes the p110 alpha subunit of the phosphatidylinositol 3-kinase protein. There are phosphatidylinositol 3-kinase CA mutations in several types of human tumors, and they are frequently observed in breast cancer. However, these mutations have not been investigated in Brazilian breast cancer patients. METHODS: PCR-SSCP and direct DNA sequencing were performed to identify phosphatidylinositol 3-kinaseCA exon 9 and exon 20 mutations in 86 patients with sporadic breast cancer. The relationships between PIK3CA mutations and patient clinicopathological characteristics and survival were analyzed. The presence of the TP53 mutation was also examined. RESULTS: Twenty-three (27%) of the 86 primary breast tumors contained PIK3CA mutations. In exons 9 and 20, we identified the hotspot mutations E542K, E545K, and H1047R, and we identified two new missense mutations (I1022V and L1028S) and one nonsense (R992X) mutation. Phosphatidylinositol 3-kinase CA exon 20 mutations were associated with poor overall survival and TP53 gene mutations. CONCLUSIONS: Phosphatidylinositol 3-kinase CA mutations are common in tumors in Brazilian breast cancer patients, and phosphatidylinositol 3-kinase CA and TP53 mutations are not mutually exclusive. Phosphatidylinositol 3-kinase CA exon 20 mutations are associated with poor survival, and they may be useful biomarkers for identifying breast cancer patients with aggressive tumors and for predicting the response to treatment with PI3K pathway inhibitors.

Is it safe to utilize in vitro reconstituted human oral epithelium? An oncogenetic pathway study

Cell therapy is a therapeutic strategy used to replace or repair damaged tissue. The epithelium transplantation of cultivated keratinocytes has been applied to several modalities of reconstruction, like oral, urethra and ocular surface. Life and death signals work coordinately to ensure cellular quality control and the viability of an organism. The aim of this study is to verify that culture conditions did not induce genetic mutations through the analysis of the key genes: pAKT, Pten, p53 and MDM2 and investigate the presence of the related proteins in human oral keratinocytes obtained by primary culture and in vitro cultivated. Formalin fixed and paraffin embedded tissues from the oral cavity were utilized as control for normal expression of the related markers and two oral squamous cell carcinoma cell lines provided the expression pattern of the proposed markers in the event of cellular transformation. Akt, PTEN, p53 and MDM2 immunohistochemistry and Western-Blotting analyzes were performed. The results showed the expression levels and intracellular localizations of the four proteins evaluated. These analyzes confirmed that the produced in vitro epithelium is bio-compatible for its utilization as reconstruction and reparatory tissue, however further analyses and additional research on other biomarkers should be performed to analyse the long term engraftment of transplantable primary culture of oral keratinocytes and the long term resistance to cellular transformation.

Nitroglycerin drives endothelial nitric oxide synthase activation via the phosphatidylinositol 3-kinase/protein kinase B pathway

Nitroglycerin (GIN) has been clinically used to treat angina pectoris and acute heart episodes for over 100 years. The effects of GTN have long been recognized and active research has contributed to the unraveling of numerous metabolic routes capable of converting GIN to the potent vasoactive messenger nitric oxide. Recently, the mechanism by which minute doses of GIN elicit robust pharmacological responses was revisited and eNOS activation was implicated as an important route mediating vasodilation induced by low GTN doses (1-50 nM). Here, we demonstrate that at such concentrations the pharmacologic effects of nitroglycerin are largely dependent on the phosphatidylinositol 3-kinase, Akt/PKB, and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) signal transduction axis. Furthermore, we demonstrate that nitroglycerin-dependent accumulation of 3,4,5-InsP(3), probably because of inhibition of PTEN, is important for eNOS activation, conferring a mechanistic basis for GIN pharmacological action at pharmacologically relevant doses. (C) 2011 Elsevier Inc. All rights reserved.

Accumulation of the SET protein in HEK293T cells and mild oxidative stress: cell survival or death signaling

SET protein (I2PP2A) is an inhibitor of PP2A, which regulates the phosphorylated Akt (protein kinase B) levels. We assessed the effects of SET overexpression in HEK293T cells, both in the presence and the absence of mild oxidative stress induced by 50 mu M tert-butyl hydroperoxide. Immunoblotting assays demonstrated that SET accumulated in HEK293T cells and increased the levels of phosphorylated Akt and PTEN; in addition, SET decreased glutathione antioxidant defense of cell and increased expression of genes encoding antioxidant defense proteins. Immunofluorescence analysis demonstrated that accumulated SET was equally distributed in cytoplasm and nucleus; however, in cells that had been exposed to oxidative stress, SET was found in large aggregates in the cytoplasm. SET accumulation in HEK293T cells correlated with inhibition of basal apoptosis as evidenced by a decrease in annexin V staining and activity of caspases; under mild oxidative stress, SET accumulation correlated with caspase-independent cell death, as evidenced by increased PI and annexin V/PI double staining. The results suggest that accumulated SET could act via Akt/PTEN either as cell survival signal or as oxidative stress sensor for cell death.

Impact of complex NOTCH1 mutations on survival in paediatric T-cell leukaemia

Background: Molecular alterations occur frequently in T-ALL and the potential impact of those abnormalities on outcome is still controversial. The current study aimed to test whether NOTCH1 mutations and additional molecular abnormalities would impact T-ALL outcome in a series of 138 T-ALL paediatric cases. Methods: T-ALL subtypes, status of SIL-TAL1 fusion, ectopic expression of TLX3, and mutations in FBXW7, KRAS, PTEN and NOTCH1 were assessed as overall survival (OS) and event-free survival (EFS) prognostic factors. OS and EFS were determined using the Kaplan-Meier method and compared using the log-rank test. Results: The frequencies of mutations were 43.5% for NOTCH1, while FBXW7, KRAS and PTEN exhibited frequencies of 19.1%, 9.5% and 9.4%, respectively. In 78.3% of cases, the coexistence of NOTCH1 mutations and other molecular alterations was observed. In multivariate analysis no statistical association was revealed between NOTCH1 mutations and any other variable analyzed. The mean length of the follow-up was 68.4 months and the OS was 50.7%. SIL-TAL1 was identified as an adverse prognostic factor. NOTCH1 mutation status was not associated with outcome, while the presence of NOTCH1 complex mutations (indels) were associated with a longer overall survival (p = 0.031) than point mutations. Conclusion: NOTCH1 mutations alone or in combination with FBXW7 did not impact T-ALL prognosis. Nevertheless, complex NOTCH1 mutations appear to have a positive impact on OS and the SIL-TAL1 fusion was validated as a negative prognostic marker in our series of T-ALL.

Analisi genetico-molecolare dei linfomi a cellule T periferiche

Molecular profiling of Peripheral T-cell lymphomas not otherwise specified Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of tumors that the WHO classification basically subdivides into specified and not otherwise specified (NOS). In Western countries, they represent around 12% of all non-Hodgkin's lymphomas. In particular, PTCL/NOS is the commonest subtype, corresponding to about 60-70% of all T-cell lymphomas. However, it remains a complex entity showing great variety regarding either morphology, immunophenotype or clinical behavior. Specially, the molecular pathology of these tumors is still poorly known. In fact, many alteration were found, but no single genes were demonstrated to have a pathogenetic role. Recently, gene expression profiling (GEP) allowed the identification of PTCL/NOS-associated molecular signatures, leading to better understanding of their histogenesis, pathogenesis and prognostication. Interestingly, proliferation pathways are commonly altered in PTCLs, being highly proliferative cases characterized by poorer prognosis. In this study, we aimed to investigate the possible role in PTCL/NOS pathogenesis of selected molecules, known to be relevant for proliferation control. In particular, we analyzed the cell cycle regulators PTEN and CDKN1B/p27, the NF-kB pathway, and the tyrosin kinase PDGFR. First, we found that PTEN and p27 seem to be regulated in PTCL/NOS as in normal T-lymphocytes, as to what expression and cellular localization are concerned, and do not present structural abnormalities in the vast majority of PTCL/NOS. Secondly, NF-kB pathway appeared to be variably activated in PTCL/NOS. In particular, according to NF-kB gene expression levels, the tumors could be divided into two clusters (C1 and C2). Specially, C1 corresponded to cases presenting with a global down-regulation of the entire pathway, while C2 showed over-expression of genes involved in TNF signaling. Notably, by immunohistochemistry, we showed that either the canonical or the alternative NK-kB pathway were activated in around 40% of cases. Finally, we found PGDFRA to be consistently over-expressed (at mRNA and protein level) and activated in almost all PTCLs/NOS. Noteworthy, when investigating possible causes for PDGFRA deregulation, we had evidences that PDGFR over-expression is due to the absence of miR-152, which appeared to be responsible for PDGFRA silencing in normal T-cells. Furthermore, we could demonstrate that its aberrant activation is sustained by an autocrine loop. Importantly, this is the first case, to the best of our knowledge, of hematological tumor in which tyrosin kinase aberrant activity is determined by deregulated miRNA expression and autocrine loop activation. Taken together, our results provide novel insight in PTCL/NOS pathogenesis by opening new intriguing scenarios for innovative therapeutic interventions.

The role of mitochondria in the regulation of gamma rays induced mTOR-dependent senescence

The first aims of this study were to demonstrate if mitochondrial biogenesis and senescence can be induced simultaneously in cell lines upon exposure to a genotoxic stress, and if the presence of mtDNA mutations which impair the functionality of respiratory complexes can influence the ability of a cell to activate senescence. The data obtained on the oncocytic model XTC.UC1 demonstrated that the presence of mitochondrial dysfunction is involved in the maintenance of a senescent phenotype induced by γ-rays treatment. The involvement of mTORC1 in the regulation of senescence has been shown in this cell line. On the other hand, in cells which do not present mitochondrial dysfunction it has been verified that genotoxic stress determines the activation of both mitochondrial biogenesis and senescence. Further studies are necessary in order to verify if mitochondrial biogenesis sustains the activation of senescence. The second aim of this thesis was to determine the involvement of mTORC1 in the regulation of PGC-1α expression, in order to verify what is the cause of the development of oncocytoma in patients affected by two hereditary cancer syndromes; Cowden and Birt-hogg-Dubé . The study of oncocytic tumors developed by patients affected by these syndromes suggested that the double heterozigosity of the two causative genes, PTEN and FLCN respectively, induce the activation of mTORC1 and therefore the activation of PGC-1α expression. On XTC.UC1 cell line, the most suitable in vitro model, experiments of complementation of PTEN and FLCN were conducted. To date, these results demonstrated that mTORC1 is not involved in the regulation of PGC-1α expression, and PTEN and FLCN seem to have opposite effect on PGC-1α expression.